Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea

다국어 초록 (Multilingual Abstract)

Background: Delamanid, bedaquiline, and linezolid have recently been approved for the treatment of multidrug- and extensively drug-resistant (MDR and XDR, respectively) tuberculosis (TB). To use these drugs effectively, drug susceptibility tests, including rapid molecular techniques, are required for accurate diagnosis and treatment. Furthermore, mutation analyses are needed to assess the potential for resistance. We evaluated the minimum inhibitory concentrations (MICs) of these three anti-TB drugs for Korean MDR and XDR clinical strains and mutations in genes related to resistance to these drugs.
Methods: MICs were determined for delamanid, bedaquiline, and linezolid using a microdilution method. The PCR products of drug resistance-related genes from 420 clinical Mycobacterium tuberculosis strains were sequenced and aligned to those of M. tuberculosis H37Rv.
Results: The overall MICs for delamanid, bedaquiline, and linezolid ranged from ≤0.025 to >1.6 mg/L, ≤0.0312 to >4 mg/L, and ≤0.125 to 1 mg/L, respectively. Numerous mutations were found in drug-susceptible and -resistant strains. We did not detect specific mutations associated with resistance to bedaquiline and linezolid. However, the Gly81Ser and Gly81Asp mutations were associated with resistance to delamanid.
Conclusions: We determined the MICs of three anti-TB drugs for Korean MDR and XDR strains and identified various mutations in resistance-related genes. Further studies are needed to determine the genetic mechanisms underlying resistance to these drugs.

참고문헌 (Reference)

1 Beckert P, "rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains" 56 : 2743-2745, 2012

2 Gu B, "The emerging problem of linezolid-resistant Staphylococcus" 68 : 4-11, 2013

3 CLSI, "Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. 2nd edition. CLSI M24-A2"

4 Huitric E, "Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor" 54 : 1022-1028, 2010

5 Matsumoto M, "OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice" 3 : e466-, 2006

6 Segala E, "New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure" 56 : 2326-2334, 2012

7 Zhang S, "Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid" 60 : 2542-2544, 2016

8 Haver HL, "Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis" 59 : 5316-5323, 2015

9 Stinson K, "MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration" 60 : 3316-3322, 2016

10 Birmingham MC, "Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program" 36 : 159-168, 2003

11 Hillemann D, "In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants" 52 : 800-801, 2008

12 Huitric E, "In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor" 51 : 4202-4204, 2007

13 Huang TS, "In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years" 52 : 2226-2227, 2008

14 Feuerriegel S, "Impact of fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824" 55 : 5718-5722, 2011

15 World Health Organization, "Global tuberculosis report 2016"

16 Keller PM, "Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST" 59 : 4352-4355, 2015

17 이승헌, "Detection of First-Line Anti-Tuberculosis Drug Resistance Mutations by Allele-Specific Primer Extension on a Microsphere-Based Platform" 대한진단검사의학회 35 (35): 487-493, 2015

18 Blair HA, "Delamanid: a review of its use in patients with multidrug-resistant tuberculosis" 75 : 91-100, 2015

19 Schena E, "Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtiter assay and the BACTECTM MGITTM 960 system" 71 : 1532-1539, 2016

20 Gler MT, "Delamanid for multidrug-resistant pulmonary tuberculosis" 366 : 2151-2160, 2012

21 European Committee on Antimicrobial Susceptibility Testing, "Definitions of clinical breakpoints and epidemiological cut-off values. Clinical Breakpoints Table V.7.1. Valid From 2017-03-10"

22 Bloemberg GV, "Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis" 373 : 1986-1988, 2015

23 Andries K, "Acquired resistance of Mycobacterium tuberculosis to bedaquiline" 9 : e102135-, 2014

24 Kaniga K, "A multilaboratory, multicountry study to determine bedaquiline minimal inhibitory concentration quality control ranges for phenotypic drug-susceptibility testing" 54 : 2956-2962, 2016

25 Andries K, "A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis" 307 : 223-227, 2005